BGI Genomics Pays $50 Million for China Rights to Natera Cancer Test
publication date: Mar 11, 2019
BGI Genomics of Shenzhen formed a $50 million partnership with US-based Natera to commercialize Natera's Signatera™ MRD (minimal residual disease) test in China. Natera says Signatera is the first circulating tumor DNA test designed to monitor molecular treatment and assess MRD. The two companies will also work together to develop reproductive health tests in select markets on BGI's sequencing instruments using its DNBseq™ NGS technology platform. Under the 10-year agreement, BGI will pay Natera $50 million, made up of upfront licensing fees, prepaid royalties, and future milestones. More details....
Stock Symbols: (SHZ: 300696) (NSDQ: NTRA)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.